300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Mobile
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Beauty
Fashion
Infrastructure
Medical
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Web3
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
Recruiting
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Enterprise
Biotech
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Egypt
Brazil
Singapore
Burkina Faso
Africa
LATAM
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
New Zealand
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Genesys Capital, VC Fund

Genesys Capital

VC Fund

Toronto, Canada

Genesys Capital is a VC fund in Toronto focused on Biotechnology and Health Care. Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising biotechnology investment opportunities.

Total investments:
35
Last investment:
Lead investor:
17%
Fund size:
$125M
Last fund:

Last updated:

Industries Genesys Capital invests in

BiotechnologyHealth CareMedicalTherapeuticsPharmaceutical

Stages Genesys Capital invests in

Series ASeries BFunding RoundSeries CVenture - Series Unknown

Countries Genesys Capital invests in

CanadaUnited States

Round sizes

Series A $1.8M–$21MSeries B $10M–$105M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$1.8M–$21M
Series B
$10M–$105M

Investment Focus

Industry

  • Biotechnology 18 (51%)
  • Health Care 13 (37%)
  • Medical 8 (23%)
  • Therapeutics 8 (23%)
  • Pharmaceutical 7 (20%)
See all 15 industries →

Stage

  • Series A 10 (29%)
  • Series B 9 (26%)
  • Funding Round 5 (14%)
  • Series C 3 (9%)
  • Venture - Series Unknown 3 (9%)
See all 8 stages →

Country

  • Canada 10 (29%)
  • United States 8 (23%)

Team

NameTitleInvestmentsLinksEmail
Damian Lamb
Damian Lamb Co-Founder and Managing Director
Co-Founder and Managing Director Total investments: 1 Find email
Jamie Stiff Managing Director
Managing Director Total investments: 8
Find email
Jennifer Williams
Jennifer Williams Partner and CFO; Director of Finance and Operations
Partner and CFO; Director of Finance and Operations Total investments: 0
Find email
Kelly Holman
Kelly Holman Co-Founder and Managing Director
Co-Founder and Managing Director Total investments: 0
Find email
Maxime Ranger
Maxime Ranger Venture Partner
Venture Partner Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
Enspire DBS Therapy supports stroke recovery patients using deep brain stimulation with physical rehabilitation to restore motor function. Enspire DBS offers a robust method to mediate the effects of stimulation and stroke rehabilitation. $10.3M / Series B / Jan 13, 2026
Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. $21M / Series B / Sep 04, 2024
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. $20M / Series C / Mar 19, 2024
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. $24M / Jun 20, 2023
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. $69.3M / Series C / Oct 17, 2022
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. $16.6M / Series A / Jun 16, 2021
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. $12.4M / Seed / May 21, 2021
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. $14M / Venture - Series Unknown / Feb 02, 2021
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. $35M / Series B / Sep 08, 2020
We passionately believe that infectious disease patients should be treated with the same precision that cancer patients receive today. As our population increases, our economies become more global, and we continue over-usage of broad-spectrum antibiotics, infectious diseases are going to continue to spread and become more pernicious. Our clinicalpractices must evolve with disease to become more precise in our diagnostic and treatment tools. At IDbyDNA, our goal is to accelerate these solutions and uncover the microbial world to reduce infectious disease-associated morbidity and mortality $20M / Series B / Jan 29, 2020
See all 35 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Mobile
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Beauty
Fashion
Infrastructure
Medical
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Web3
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
Recruiting
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Enterprise
Biotech
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Egypt
Brazil
Singapore
Burkina Faso
Africa
LATAM
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
New Zealand
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Genesys Capital invest in?

Genesys Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 35 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Genesys Capital invest in?

Genesys Capital typically joins rounds of $1.8M–$21M at Series A and $10M–$105M at Series B. These are whole funding-round sizes, not Genesys Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Genesys Capital took part in.

How do I contact Genesys Capital?

Public channels for Genesys Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Genesys Capital?

The team at Genesys Capital includes Damian Lamb (Co-Founder and Managing Director), Jamie Stiff (Managing Director) and Jennifer Williams (Partner and CFO; Director of Finance and Operations). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Genesys Capital Genesys Capital Find emails